NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/04/2023
Back to search
Official data from USPTO
XPAC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
04/04/2023
Classification
Registered
Trademark type
Word
Nice classes
1, 5
Filing date
08/30/2021
Registration date
04/04/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/04/2023
Last transaction
04/04/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2020-08-00
First use in commerce
2020-08-00
Drawing code
4
Owner type
03
Owner location
South San Francisco, CA
Examiner
PAYABYAB, EDWARD TAN
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Amunix Pharmaceuticals, Inc.
Representatives
Nicole E. Reifman MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in the manufacture of pharmaceuticals; reagentsenzymesnucleotides for scientific or medical research; protein polymeric intermediates for use in the manufacture of pharmaceutical preparations; biomedical compoundspeptidespeptidomimeticsprotein polymeric intermediates used in the manufacture of pharmaceutical preparations
Class 5
Pharmaceutical preparations for the treatment of cancerousinflammatoryimmunologicalviral diseases; pharmaceutical preparations for use in the field of oncologyimmunologyinflammation for the treatment of cancerasthmaatopic dermatitisperipheral inflammatory diseasescardiovascular diseaseautoimmune diseases; medical diagnostic reagents; reagents for use in testing proteins for medical and diagnostic purposes
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/17/2023
PUBO
PUBLISHED FOR OPPOSITION
01/17/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/28/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2022
GNRT
NON-FINAL ACTION E-MAILED
06/02/2022
CNRT
NON-FINAL ACTION WRITTEN
06/02/2022
DOCK
ASSIGNED TO EXAMINER
06/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/13/2021
NWAP
NEW APPLICATION ENTERED
09/02/2021
Continuous trademark protection
Get notified about every new filing that threatens XPAC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.